Abstract: A disc changing system for a robotic defect repair system is presented. The system has a first abrasive disc and a second abrasive disc. The first and second abrasive discs are coupled to a liner. The system includes an abrasive disc placement device configured to automatically: remove the first abrasive disc from the liner, transport the first abrasive disc to a robotic tool of the robotic defect repair system, and place the first abrasive disc on a backup pad coupled to the robotic tool. The system also includes an abrasive disc remover configured to automatically remove the first abrasive disc after receiving a removal signal. The system also includes a controller configured to send an instruction to the disc placement device to remove, transport and place the first abrasive disc, instruct the robotic tool to conduct an abrasive operation. The controller is also configured to send the removal signal.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: A device for producing a trabecular fiber within a ventricle of a heart. The device includes a substrate and a first tissue anchor connected to the substrate. The substrate is formed of a non-rigid material.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being absorbed, thereby reducing the total caloric load to assist in weight management.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: A device for producing a trabecular fiber within a ventricle of a heart. The device includes a substrate and a first tissue anchor connected to the substrate. The substrate is formed of a non-rigid material.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system, through the gastrointestinal system, or redirected outside the body. The device may include a valve to control a flow of the fluid. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being metabolized and absorbed, thereby reducing the total caloric load to assist in weight management and/or for prevention/treatment of atherosclerosis.

Abstract: A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being absorbed, thereby reducing the total caloric load to assist in weight management.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being absorbed, thereby reducing the total caloric load to assist in weight management.

Abstract: Described is an implantable medical device comprising housing having a distal end and a proximal end, the proximal end fixedly coupled to the distal end of the lead body, a coupler rotatably disposed within the housing, the coupler having a proximal end and a distal end, and a helical electrode fixedly secured to the distal end of the coupler. The helical electrode comprises a proximal axial length portion that comprises a non-degradable material, and a distal axial length portion that comprises a biodegradable material. The proximal and distal portions may include concave/convex surfaces or threaded portions. The coupler and the helical electrode are configured to rotate and therefore translate relative to the housing.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system, through the gastrointestinal system, or redirected outside the body. The device may include a valve to control a flow of the fluid. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being metabolized and absorbed, thereby reducing the total caloric load to assist in weight management and/or for prevention/treatment of atherosclerosis.

Abstract: Described is an implantable lead comprising a flexible body extending between a proximal end and a distal end and a distal assembly coupled to the distal end of the body. The distal assembly includes a housing having a distal end and a proximal end, the proximal end fixedly coupled to the distal end of the lead body, a coupler rotatably disposed within the housing, the coupler having a proximal end and a distal end, and a helical electrode fixedly secured to the distal end of the coupler. The helical electrode comprises a proximal axial length portion that comprises a non-degradable material, and a distal axial length portion that comprises a biodegradable material. The coupler and the helical electrode are configured to rotate and therefore translate relative to the housing.

Abstract: Implantable leadless pacing devices and medical device systems including an implantable leadless pacing device are disclosed. An example implantable leadless pacing device may include a pacing capsule. The pacing capsule may include a housing. The housing may have a proximal region and a distal region. A first electrode may be disposed along the distal region. An anchoring member may be coupled to the distal region. One or more anti-rotation members may be fixedly attached to the distal region.

Abstract: Described is an implantable lead comprising a flexible body extending between a proximal end and a distal end and a distal assembly coupled to the distal end of the body. The distal assembly includes a housing having a distal end and a proximal end, the proximal end fixedly coupled to the distal end of the lead body, a coupler rotatably disposed within the housing, the coupler having a proximal end and a distal end, and a helical electrode fixedly secured to the distal end of the coupler. The helical electrode comprises a proximal axial length portion that comprises a non-degradable material, and a distal axial length portion that comprises a biodegradable material. The coupler and the helical electrode are configured to rotate and therefore translate relative to the housing.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being absorbed, thereby reducing the total caloric load to assist in weight management.

Abstract: Described is an implantable lead comprising a flexible body extending between a proximal end and a distal end and a distal assembly coupled to the distal end of the body. The distal assembly includes a housing having a distal end and a proximal end, the proximal end fixedly coupled to the distal end of the lead body, a coupler rotatably disposed within the housing, the coupler having a proximal end and a distal end, and a helical electrode fixedly secured to the distal end of the coupler. The helical electrode comprises a proximal axial length portion that comprises a non-degradable material, and a distal axial length portion that comprises a biodegradable material. The coupler and the helical electrode are configured to rotate and therefore translate relative to the housing.